Back to top

Image: Bigstock

Abbott Laboratories

Read MoreHide Full Article

Over the last three months, Abbott is trading below the broader Medical Products industry. While, sluggish pediatric business in China continues to hamper growth, we are also worried about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters. On a positive note, we are optimistic about its strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Abbott Laboratories (ABT) - free report >>